Abstract: The invention discloses a method for treatment of epilepsy-associated motor symptom and/or cognitive impairment, by co-administering clavulanic acid and valproic acid to an epilepsy subject in need thereof. Clavulanic acid can be administrated in a dosage of 0.016-10 mg/kg/day, while valproic acid can be administrated in a dosage of 0.8-30 mg/kg/day. Moreover, clavulanic acid and valproic acid can be administrated concurrently, sequentially, separately, continuously or intermittently. In addition, clavulanic acid, as well as valproic acid, can be administrated orally or parenterally.

Abstract: The invention discloses a pharmaceutical composition, including clavulanic acid and valproic acid, for treatment of epilepsy seizure and/or for treatment of epilepsy-associated motor symptom and cognitive impairment. The invention also discloses a method treatment of epilepsy seizure and/or for treatment of epilepsy-associated motor symptom and cognitive impairment, by co-administering clavulanic acid and valproic acid to a subject in need thereof.

Abstract: A method for treating dementia with Lewy bodies (DLB) comprises administrating ceftriaxone to a subject in need thereof to treat the DLB syndromes such as cognitive decline and neurological deficit in the subject in need thereof. Ceftriaxone can be parenterally or orally administrated to the subject in a dosage of 1.5-35 mg/kg/day.

Abstract: The invention discloses a pharmaceutical composition for treating Parkinson's disease dementia (PDD), which including erythropoietin and ceftriaxone. The invention also discloses a use of the pharmaceutical composition in the manufacture of a medicament for the treatment of PDD.

Abstract: Disclosed herein is a method for treatment of a human subject having or suspected of having Parkinson's disease dementia, which includes administering to the human subject ceftriaxone at a daily dosage ranging from about 1.5 mg to about 35 mg per kilogram of a body weight of the human subject.

Abstract: Disclosed herein is a method for treatment of a human subject having or suspected of having Parkinson's disease dementia, which includes administering to the human subject ceftriaxone at a daily dosage ranging from about 1.5 mg to about 35 mg per kilogram of a body weight of the human subject.

Abstract: Disclosed herein is a composition for improving at least one of cognitive deficits associated with menopausal syndrome, which includes diosgenin. Also disclosed herein is a method for improving at least one of cognitive deficits associated with menopausal syndrome in a subject via administering the aforesaid composition.

Abstract: The present invention provides a method of treating a neurodegenerative disorder in a patient, comprising administration to the patient a therapeutically effective amount of D-cycloserine and its derivatives.